Juvelook vs Rejuran: differences and questions to ask
Juvelook combines poly-D,L-lactic acid (PDLLA) with hyaluronic acid (HA); Rejuran is a polynucleotide (PN) product family. They differ in material and formulation. The studies below examine different treatments and questions, so they cannot tell you which product would work better for you. Start with the exact variant, the concern being treated and the evidence for that plan.
Written by the Seoul Skin Boosters editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed: .
How do Juvelook and Rejuran differ?
| Comparison | Juvelook | Rejuran |
|---|---|---|
| Main material | PDLLA with hyaluronic acid | Polynucleotides; HB plus also contains hyaluronic acid |
| Names to distinguish | Juvelook, Juvelook Volume and Juvelook i | Rejuran, Rejuran i, Rejuran S and Rejuran HB plus |
| Study discussed below | A prospective study of PDLLA-HA for under-eye hollows | A randomised study comparing PN with non-cross-linked HA around the eyes |
| What to verify | The variant, amount per vial and prepared volume | The variant, formulation and amount per syringe |
| What remains unanswered | Whether it outperforms Rejuran for your concern | Whether it outperforms Juvelook for your concern |
The Juvelook material and variant guide and Rejuran formulation guide set out the product records behind these names. HA means hyaluronic acid; PDLLA and PN name different materials. A shared “skin booster” label does not make the formulations equivalent.
What does the evidence actually compare?
The PN trial enrolled 27 adults and compared PN on one side of the eye area with non-cross-linked HA on the other. It was randomised and used three treatments two weeks apart. Its comparator was HA, not Juvelook (2022; PMID 32248707).
The Juvelook study followed 15 women receiving three treatments of the 50 mg PDLLA-HA product for under-eye hollows. It assessed changes within that group and had no Rejuran comparison group (2026; PMID 42098500).
Neither study directly compares Juvelook with Rejuran. Their different designs cannot establish a winner for effectiveness, recovery time or safety. Ask whether the evidence matches the exact product, treatment area and outcome proposed for you.
What should you discuss with a clinician?
- Name the concern you want assessed, such as texture, fine lines or hollowness, and ask how the proposed treatment addresses it.
- Bring your treatment history, including products already used in the area, and discuss medicines, allergies and previous reactions.
- Ask about common reactions, serious complications, warning signs and who to contact if a problem develops after you leave Seoul.
- Ask how the clinician would judge progress and when they would reconsider the plan.
How should you compare a course and a total quote?
- Which exact product and variant does the quote cover? Ask to confirm the formulation before comparing amounts.
- How many vials or syringes are included, and what does the stated volume represent?
- How many visits are proposed, how far apart, and what happens if you cannot return on that schedule?
- What is the total quoted cost, including any separate consultation, anaesthesia, follow-up or additional-session charges?
- What recovery time should you allow before travel or an event, and how will follow-up work after you return home?
What should a Seoul consultation clarify?
Use the Rejuran product information and consultation questions to prepare questions about the PN option. Confirm the current variant, availability, treatment area, proposed course and written quote directly with the clinic.
Questions about the comparison
Are Juvelook and Rejuran the same type of product?
No. Juvelook combines PDLLA and hyaluronic acid, while Rejuran is a polynucleotide product family. Check the full variant name: formulations within each family also differ.
What evidence supports the differences described here?
Product records identify the different materials. The PN trial (PMID 32248707) compares PN with HA; the Juvelook study (PMID 42098500) follows a PDLLA-HA treatment group. Neither is a direct Juvelook–Rejuran comparison.
What should a Seoul consultation clarify?
The concern being assessed, exact product and variant, availability, supporting evidence, amount, risks, number and spacing of visits, total quoted cost and arrangements for follow-up after travel.
Study records checked 18 October 2026
Lee YJ, Kim HT, Lee YJ, et al. Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation: a randomized, double-blind, split-face trial. J Dermatolog Treat. 2022;33(1):254-260. PMID: 32248707. DOI: 10.1080/09546634.2020.1748857.
Young SM, Lau EKH. Hybrid Biostimulator and Hyaluronic Acid Injectable for Tear Trough Rejuvenation. Aesthetic Plast Surg. 2026;50(13):5337-5343. PMID: 42098500. DOI: 10.1007/s00266-026-05817-z.